Popular Trials
Amino Acid
Levocarnitine for Dry Eye in Sjogren's Syndrome
This trial tests levocarnitine, a supplement that helps transport carnitine into cells, in adults with Sjogren's syndrome who have dry eyes. Sjogren's syndrome causes dryness in the eyes and mouth. Levocarnitine may help by increasing carnitine levels in tears, potentially reducing eye dryness and improving comfort. Levocarnitine is a molecule required in mammalian energy metabolism, facilitating the transport of long-chain fatty acids across the mitochondrial membrane for energy production.
Popular Filters
Trials for SS Patients
Dazodalibep for Sjögren's Syndrome
This trial is testing dazodalibep, a medication, to see if it can help people with moderate-to-severe Sjögren's Syndrome. The goal is to reduce their symptoms and improve their quality of life. Researchers will also check if the medication is safe and well-tolerated by patients.
Monoclonal Antibodies
Ianalumab for Sjogren's Syndrome
This trial is to measure long-term safety of ianalumab in participants with Sjogrens syndrome for up to 5 years; ianalumab will be given monthly or every 3 months (w/placebo in between). 600 participants will be enrolled. Some may self-inject at home.
Behavioural Intervention
Supportive Care for Arthritis
This trial tests whether providing tailored lists of resources and/or a specialized nurse navigator to patients with inflammatory arthritis and SDoH-related needs can reduce missed appointments and improve health outcomes.
Trials for Sjögren's Syndrome Patients
Monoclonal Antibodies
Ianalumab for Sjogren's Syndrome
This trial is to measure long-term safety of ianalumab in participants with Sjogrens syndrome for up to 5 years; ianalumab will be given monthly or every 3 months (w/placebo in between). 600 participants will be enrolled. Some may self-inject at home.
Frequently Asked Questions
Introduction to sjogren's syndrome
What are the top hospitals conducting sjogren's syndrome research?
When it comes to advancing research and treatment options for individuals living with Sjogren's syndrome, several hospitals are taking the lead. In Van Nuys, California, the Novartis Investigative Site is making significant strides with two ongoing clinical trials focused on this complex autoimmune disorder. Although they have only recorded a total of two trials in their history, this hospital's commitment to exploring new avenues for Sjogren's syndrome began as recently as 2022.
Meanwhile, another branch of the Novartis Investigative Site located in Houston is also dedicated to studying and improving outcomes for individuals with Sjogren's syndrome. With two active clinical trials and a total of four conducted over time since their first endeavor started in 2017.
In Denver, Colorado, the Denver Arthritis Clinic has emerged as another key player in researching treatments specifically tailored to address the challenges faced by those diagnosed with Sjogren's syndrome. They currently have two ongoing clinical trials alongside an impressive track record of four completed studies after initiating their first trial back in 2016.
Similarly contributing towards advancements in understanding and managing Sjogren’s syndrome is West Tennessee Research Institute situated at Jackson which holds expertise within this field where they conduct around five such experiments from starting its voyage concerning sjögrens investigational specimens dating back till2016.
Moreover,the prestigious National Institutes of Health Clinical Center located in Bethesda aims at tackling various medical conditions including sjögrens thus holding themselves accountable by conducting seriesof comprehensive examinations through multiple investigations.Alongside having a noteworthy contribution being actively involved into developmentof apropos therapeutic strategies guidedby twocurrentclinicaltrials;their journey starts way earlier than others duringthe yearof2012with initiation regarding these evaluations
Through these collective efforts across different locations nationwide; medical professionals and researchers hope to unravel further insights into Sjogren's syndrome - addressing symptoms such as dry eyes or mouth while striving relentlessly to discover more effective and personalized treatment options. By shedding light on this lesser-known condition, they offer hope to individuals living with Sjogren's syndrome and pave the way for a better future where challenges posed by autoimmune disorders can be effectively managed
Which are the best cities for sjogren's syndrome clinical trials?
When it comes to sjogren's syndrome clinical trials, several cities stand out as hubs for ongoing research. Duncansville in Pennsylvania and Houston in Texas offer 5 active trials each, investigating treatments like SAR441344, Arm A, Nipocalimab, Nivolumab, and Tivanisiran sodium ophthalmic solution. Boston in Massachusetts follows closely with 4 active trials focusing on interventions such as Nivolumab and different treatment arms. Additionally, Memphis in Tennessee and Jacksonville in Florida both have 4 ongoing trials centered around medications like SAR441344, Nipocalimab, and Tivanisiran sodium ophthalmic solution. These cities provide individuals suffering from sjogren's syndrome access to cutting-edge research opportunities that hold the promise of improved care outcomes.
Which are the top treatments for sjogren's syndrome being explored in clinical trials?
Sjogren's syndrome, a complex autoimmune condition, is the focus of ongoing clinical trials exploring potential treatment options. Among these, nipocalimab stands out as a promising contender with its active trial and debut in 2021. Additionally, cyclosporine 0.09% ophthalmic solution demonstrates potential benefits for Sjogren's syndrome patients through its own active trial and first listing this year. Tofacitinib also shows promise in treating this condition, with an ongoing clinical trial dedicated to investigating its efficacy specifically for Sjogren's syndrome. As researchers delve deeper into these treatments' potential, newfound hope emerges for individuals grappling with the challenges posed by Sjogren's syndrome.
What are the most recent clinical trials for sjogren's syndrome?
Exciting advancements are underway in the field of Sjogren's syndrome, with recent clinical trials offering new hope for patients. One such trial is investigating Deucravacitinib at Dose 1, a potential treatment that has entered Phase 3. Another promising study involves ADX-629, which is being evaluated in both Phase 1 and Phase 2 trials to assess its effectiveness against Sjogren's syndrome. Additionally, Arm A is undergoing Phase 3 testing as a potential therapy for this condition. These ongoing research efforts aim to provide better treatment options and improved quality of life for individuals living with Sjogren's syndrome.
What sjogren's syndrome clinical trials were recently completed?
Recently, several clinical trials investigating potential treatments for Sjogren's syndrome have been completed. In August 2021, the Institut de Recherches Internationales Servier concluded a trial assessing the effectiveness of S95011 concentrate for solution for infusion. Another study sponsored by Bristol-Myers Squibb tested branebrutinib and was completed in January 2020. Additionally, Viela Bio conducted a trial on VIB4920 that reached completion in October 2019, while Novartis Pharmaceuticals wrapped up their CFZ533 trial during the same month. These recent developments highlight ongoing efforts to find innovative therapies and provide hope for individuals affected by Sjogren's syndrome.